About the Authors
- Kelly C. Fahnoe
-
Current address: Department of Biochemistry and Molecular Pharmacology, Celgene Avilomics Research, Bedford, Massachusetts, United States of America
Affiliation Antibacterials Research Unit, Pfizer Worldwide Research & Development, Groton, Connecticut, United States of America
- Mark E. Flanagan
-
Affiliation Antibacterials Research Unit, Pfizer Worldwide Research & Development, Groton, Connecticut, United States of America
- Glenn Gibson
-
Current address: Department of Cardiovascular Metabolic Disease Research, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, United States of America
Affiliation Antibacterials Research Unit, Pfizer Worldwide Research & Development, Groton, Connecticut, United States of America
- Veerabahu Shanmugasundaram
-
Affiliation Antibacterials Research Unit, Pfizer Worldwide Research & Development, Groton, Connecticut, United States of America
- Ye Che
-
Affiliation Antibacterials Research Unit, Pfizer Worldwide Research & Development, Groton, Connecticut, United States of America
- Andrew P. Tomaras
-
* E-mail: andrew.tomaras@pfizer.com
Affiliation Antibacterials Research Unit, Pfizer Worldwide Research & Development, Groton, Connecticut, United States of America
Competing Interests
All authors have been employed by Pfizer, either past or present, and may own stock in the company. Pfizer was the funder for this study. There are no patents, products in development, or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: KCF MEF GG APT. Performed the experiments: KCF GG APT. Analyzed the data: KCF MEF VS YC APT. Contributed reagents/materials/analysis tools: KCF MEF VS YC. Wrote the paper: KCF MEF VS APT.